Adverse Event Report Findings
CAERS is collecting data from individuals who perceive that they have experienced an Adverse Event (AE) related to their inoculation with a COVID ‘vaccine’.
At the present time, CAERS cannot know for certain if a specific event that any individual reported as an AE is in fact an adverse event related to the inoculations. However, as more data continues to surface, patterns are emerging that may shed much more light on this. Furthermore, follow-up testing might be developed in the future that can determine if an event does relate directly to a COVID inoculation. For both of these reasons, it is critical that anyone who believes that they may have experienced an AE, report it as such. This is particularly important because the authorities responsible for the mandating of these inoculations have not engaged in any form of Active Surveillance.
Active surveillance is the process normally used in medical practice and in research. When a person is given a treatment of any type, regular contact is made with them to monitor both how much the treatment is helping, as well as how much it may be causing harm. Simply waiting for patients to report how things are going is rarely good enough because so much vital information can be missed and ineffective or harmful treatments can therefore persist. Only through active surveillance can we know how good or bad a treatment is, especially if it is experimental, and appropriate actions be taken.
It is very important to remember and realize that although statistics are ‘cold’ numbers only—all of these numbers used in the statistical analysis of CAERS data—came from real Canadian people, whose lives and their family’s lives, after the injection, have been impacted in some way (sometimes significantly). These changes are still ongoing in many situations.
Adverse Event by Age
AEs reported for all age groups—no age seems exempt.
Adverse Event Dose Onset
Although AEs are most common after the first dose, having had no reaction after the first dose does not mean that an AE cannot occur after subsequent doses (43.15%).
Reason for Taking the Inoculation
Over 50% received the inoculation as a requirement for some activity—working (41.2%) and travel (14.02%). Many people seemed to indicate that they took the inoculation more for the protection of others (social responsibility 23.4%) than primarily for themselves (7.1%). A significant number (12.1%) trusted health care professionals as their primary reason for receiving the inoculation.
Medical Attention Required
Over 97% had significant enough reactions or concerns that they made contact with a physician (no intervention only 2.9%).
Adverse Event Severity
More than 12% experienced AEs that were either life-threatening or fatal, a very large percentage. Very few were mild (only 7.3%).
The overwhelming majority of AEs were not simple, acute reactions but became chronic problems (72.9%). Only 10% consider themselves to be recovered from their AE.
Adverse Event Onset Time
Although the majority of individuals suffered an AE within one week of their inoculation, a significant percentage (14.1%) experienced it more than a month later. This is of concern because the longer the time between the inoculation and the reaction, the more difficult it may be to identify a cause-and-effect connection. For example, some conditions that might relate to the inoculations, such as auto-immune phenomena or cancers, may take a considerable period of time to develop, although in some individuals, these are occurring more quickly and are often quite aggressive.
Adverse Event Reported to Health Canada
Only a very small percentage of potential AEs were reported to Health Canada (3.91%), which is somewhat surprising given that the inoculations are still experimental and are utilizing a brand-new technology that utilizes genetic material.
The most common body systems affected are: neurologic (22.6%), cardiovascular and circulatory (27.24%), and musculoskeletal (13.41%). This is consistent with reports elsewhere in the world. However, no body system seemed to be exempt from the potential for an AE.
Number of Systems Affected Per Person
Almost 80% of those suffering an AE had more than one body system affected, and almost 30% had four or more body systems affected.
The neurological system was the most commonly affected body system with 62.42% of those submitting potential AEs reporting neurological symptoms.
Given that the data collected by CAERS qualifies as passive surveillance (dependent on individuals recognizing adverse events themselves and then reporting it voluntarily), the trends seen are of concern.
- All age groups report AEs after any of the doses received.
- Most AEs were sufficiently severe to warrant seeing a healthcare professional, and many were very serious or even lethal.
- Most became a chronic problem, and many occurred a month or more after the inoculation.
- All body systems were reported, some much more commonly. In fact, the majority of respondents indicated that more than one body system was affected, and frequently more than four.
- It is very worrying that so few AEs were reported to Health Canada.
Clearly more study must be undertaken to identify and quantify AEs from the COVID inoculations. Only by doing so can we hope to assist those individuals harmed and prevent further harm from occurring.